Latest news with #Evvy
Business Wire
03-06-2025
- Business
- Business Wire
Evvy Launches Women's Complete Probiotic, Delivering Advanced 3-in-1 Microbiome Support for Gut, Urinary, & Vaginal Health
NEW YORK--(BUSINESS WIRE)-- Evvy, the precision women's health company, today announces the launch of its latest innovation: Evvy Women's Complete Probiotic. This once-daily supplement delivers advanced 3-in-1 microbiome support for gut, vaginal and urinary health — backed by science and uniquely formulated for women. Unlike most probiotics that target just one area of health, Evvy Women's Complete Probiotic is designed to support the full microbiome ecosystem that shapes a woman's wellbeing. The probiotic includes: Clinically-studied Lactobacillus strains to promote healthy bacteria, support yeast balance, and reduce bloating Patented delayed-release capsules that increase survivability of probiotic strains through the GI tract Postbiotics and Vitamins D & E to support immunity and gut barrier integrity 'At Evvy, our research across over 50,000 women has shown just how deeply interconnected the gut, urinary, and vaginal microbiomes are — yet most products continue to treat them in isolation,' said Pita Navarro, Co-founder and Chief Science Officer at Evvy. 'That's why we created a formulation that finally reflects the science: a single research-backed capsule that supports the full picture of women's microbiome health.' The launch of the Women's Complete Probiotic builds on Evvy's pioneering vaginal healthcare platform, which includes the world's first at-home Vaginal Microbiome Test powered by metagenomic sequencing, as well as precision prescription treatments. Informed by insights from the largest real-world dataset on the vaginal microbiome, Evvy Women's Complete Probiotic is designed as a proactive daily essential for supporting gut, urinary, and vaginal health. The Women's Complete Probiotic is available for $55 for a monthly supply of 30 capsules or $44/month with a subscription. To learn more visit, About Evvy: Founded in 2021, Evvy is closing the gender health gap by leveraging overlooked female biomarkers, starting with the vaginal microbiome. The company offers the world's first Vaginal Microbiome Test powered by metagenomic sequencing, analyzing over 700 microbes with a single, at-home swab — including those related to bacterial vaginosis, yeast infections, fertility outcomes, and more. Evvy's care platform also includes precision treatment pathways from licensed clinicians and 1:1 health coaching. Through their test and care platform, Evvy has built the world's largest dataset on the vaginal microbiome, and they are leveraging this novel data to improve outcomes across women's health.
National Post
03-06-2025
- Health
- National Post
Evvy Launches Women's Complete Probiotic, Delivering Advanced 3-in-1 Microbiome Support for Gut, Urinary, & Vaginal Health
Article content Developed by the scientists behind Evvy's Vaginal Microbiome Test, the unique formulation offers targeted support for women's interconnected microbiomes Article content Article content NEW YORK — Evvy, the precision women's health company, today announces the launch of its latest innovation: Evvy Women's Complete Probiotic. This once-daily supplement delivers advanced 3-in-1 microbiome support for gut, vaginal and urinary health — backed by science and uniquely formulated for women. Article content Unlike most probiotics that target just one area of health, Evvy Women's Complete Probiotic is designed to support the full microbiome ecosystem that shapes a woman's wellbeing. The probiotic includes: Article content Clinically-studied Lactobacillus strains to promote healthy bacteria, support yeast balance, and reduce bloating Patented delayed-release capsules that increase survivability of probiotic strains through the GI tract Postbiotics and Vitamins D & E to support immunity and gut barrier integrity Article content 'At Evvy, our research across over 50,000 women has shown just how deeply interconnected the gut, urinary, and vaginal microbiomes are — yet most products continue to treat them in isolation,' said Pita Navarro, Co-founder and Chief Science Officer at Evvy. 'That's why we created a formulation that finally reflects the science: a single research-backed capsule that supports the full picture of women's microbiome health.' Article content The launch of the Women's Complete Probiotic builds on Evvy's pioneering vaginal healthcare platform, which includes the world's first at-home Vaginal Microbiome Test powered by metagenomic sequencing, as well as precision prescription treatments. Informed by insights from the largest real-world dataset on the vaginal microbiome, Evvy Women's Complete Probiotic is designed as a proactive daily essential for supporting gut, urinary, and vaginal health. Article content About Evvy: Article content Founded in 2021, Evvy is closing the gender health gap by leveraging overlooked female biomarkers, starting with the vaginal microbiome. The company offers the world's first Vaginal Microbiome Test powered by metagenomic sequencing, analyzing over 700 microbes with a single, at-home swab — including those related to bacterial vaginosis, yeast infections, fertility outcomes, and more. Evvy's care platform also includes precision treatment pathways from licensed clinicians and 1:1 health coaching. Through their test and care platform, Evvy has built the world's largest dataset on the vaginal microbiome, and they are leveraging this novel data to improve outcomes across women's health. Article content Article content Article content Article content Contacts Article content Article content Article content
Business Wire
29-04-2025
- Health
- Business Wire
Evvy Partners with Leading Fertility Clinics to Launch Landmark Study Uncovering the Role of the Vaginal Microbiome in IVF Outcomes
NEW YORK--(BUSINESS WIRE)--Evvy, a pioneering women's health startup focused on the vaginal microbiome, today announced the launch of a landmark clinical study exploring the link between the vaginal microbiome and in vitro fertilization (IVF) outcomes. This will be the first-ever study using a validated, commercially available vaginal microbiome test to uncover potential microbial markers linked to IVF success. The study was designed in collaboration with leading fertility doctors including Dr. David Sable (Life Sciences), Dr. Peter Klatsky (Spring Fertility), Dr. Sara Vaughn (HRC Fertility), and Dr. Eduardo Hariton (Reproductive Science Center), alongside Evvy's Chief Science Officer, Pita Navarro, and Chief Medical Officer, Dr. Kate McLean. Together, they aim to identify the specific vaginal markers associated with IVF outcomes. The study is already live with multiple clinics across the country with significant interest from fertility clinics and research institutions to join. Clinics or researchers interested in becoming study sites are encouraged to reach out to participate in this growing collaborative effort to advance the science of fertility. 'Despite doing everything 'right,' many IVF patients still face heartbreaking failures without clear explanations,' says Dr. Kate McLean, Chief Medical Officer at Evvy. 'This study could fundamentally enhance our understanding of why some cycles fail — and unlock a new, proactive tool for patients and providers to improve outcomes.' With roughly 1 in 8 couples facing infertility and average IVF success rates remaining around 30–40% per cycle, there's a clear and urgent need for more predictive and preventive insights in fertility care. While early research has linked vaginal microbiome disruptions to IVF failure, recurrent pregnancy loss, and preterm birth, those insights have yet to be translated into clinical practice at scale. With this study, Evvy hopes to leverage their unique testing and data platform to finally bridge the gap between research and patient care — providing answers where they didn't previously exist. Evvy's test is CLIA, CAP, and CLEP certified, and validation of the test methodology was published in the peer-reviewed Diagnostics journal. The test can detect 700+ microbes from a single, at-home swab. Through Evvy's platform, they've built the world's largest dataset on the vaginal microbiome and created a proprietary database with hundreds of novel genomes. Through this proprietary platform, Evvy is uniquely positioned to map key microbial signatures to clinical outcomes. 'Despite decades of progress in reproductive medicine, there's still so much we're learning about the underlying biology that contributes to IVF outcomes,' says Pita Navarro, Co-Founder and Chief Science Officer of Evvy. 'The vaginal microbiome has been consistently overlooked in fertility research, even as evidence grows around its role in reproductive outcomes. With this study, we hope to generate new insights that deepen our understanding and lay the scientific foundation for future tools to help doctors and their patients make more personalized, informed decisions about care.' The launch of this study builds on Evvy's recent release of fertility-focused insights, which enable users to assess and improve their vaginal microbiome before trying to conceive, undergoing IVF, or exploring causes of unexplained infertility. The company aims to build solutions based on what science already knows—and do the research where it has been overlooked. This study is the first of many in Evvy's pipeline to validate the power of vaginal microbiome testing in predicting a variety of women's health outcomes throughout the lifespan. About Evvy Evvy is closing the gender health gap through novel biomarker discovery in the vaginal microbiome. Evvy's groundbreaking Vaginal Health Test is the world's only certified, peer-reviewed vaginal microbiome test to uncover 700+ microbes with a single, at-home swab. Combined with precision treatment pathways and 1-1 coaching, Evvy provides over 50,000 women with data-driven, personalized healthcare for vaginal infections, fertility, menopause, and more. Evvy has built the world's largest dataset on the vaginal microbiome, and they are pioneering novel research to transform female health outcomes.
